Bleximenib is under investigation in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and NCT05453903 (A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies)

Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an ant…

Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.

Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) antipsychotic, it is s…

Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Blue crab allergenic extract is used in allergenic testing.

Blueberry allergenic extract is used in allergenic testing.

Bluefish allergenic extract is used in allergenic testing.

BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.

BLXA4 has been used in trials studying the treatment of Gingival Inflammation.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

Deskripsi belum tersedia.

BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).

Deskripsi belum tersedia.

BMS-184476 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.

BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.

BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3)…

BMS-275183 has been used in trials studying the treatment of Tumors and Non-small Cell Lung Cancer.

BMS-394136 has been used in trials studying the diagnostic of Heart Diseases.

BMS-488043 has been investigated as an anti-HIV agent.

BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

BMS-582949 has been investigated for the treatment of Psoriasis.

BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.

BMS-690514 has been investigated for the treatment of Breast Cancer.

BMS-741672 is under investigation in clinical trial NCT00699790 (Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance).

BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).

BMS-770767 is under investigation in clinical trial NCT01058083 (Safety Study of BMS-770767 in Subjects With Hypercholesterolemia).

BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.

BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).

BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).

BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).

BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).

Deskripsi belum tersedia.

BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.

BMS-903452 has been used in trials studying the treatment of Diabetes.

BMS-908662 has been used in trials studying the treatment of Melanoma and Colorectal Cancer.

BMS-911543 has been used in trials studying the treatment of Cancer.

BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).

BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).

BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).

BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).